Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
WADA 2026: S6.B, specified, prohibited in competition above a urine concentration of 10 micrograms/mL. The future 2027 List retains this rule. See the separate S5 combination condition. [1] [2]
2026 and 2027 List, S6.B, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Threshold and combination conditions
When a prohibited diuretic or masking agent is detected with formoterol, salbutamol, cathine, ephedrine, methylephedrine or pseudoephedrine, S5 has an additional TUE requirement even below the usual threshold. The note expressly excludes qualifying carbonic-anhydrase-inhibitor eye administration and local dental felypressin. It is not a dosing or test-clearance rule. [1] [2]
- A urine threshold cannot be converted into a safe dose or a guaranteed test result.
Botanical and supplement context
FDA’s 2004 rule declared supplements containing ephedrine alkaloids adulterated because of unreasonable illness or injury risk. This was a US dietary-supplement action, not a worldwide ban on all ephedrine medicines. [3]
- The rule is not a dose-to-test-result guide.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16 · S5 p.12
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16 · S5 p.12
- H9. FDA. Compliance guide for final ephedrine-alkaloid dietary-supplement rule, rule published 11 February 2004. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
FDA compliance guide: introduction and risk basis
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.